Enoxaparin sodium biosimilar - Rovi

Drug Profile

Enoxaparin sodium biosimilar - Rovi

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rovi
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Deep vein thrombosis; Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 30 Jun 2017 Registered for Deep vein thrombosis (Prevention) in Slovakia, Latvia, Estonia, United Kingdom (SC)
  • 30 Jun 2017 Registered for Deep vein thrombosis in Latvia, Slovakia, Estonia, United Kingdom (SC)
  • 30 Jun 2017 Registered for Myocardial infarction (Prevention) in Slovakia, Estonia, United Kingdom, Latvia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top